
Roche’s cancer pill Erivedge has received a conditional European approval for treatment of the most common type of skin cancer. …

Roche’s skin cancer candidate vismodegib has met its primary endpoint in a phase II trial. The drug is being tested …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

